Coherus Oncology, Inc. (CHRS): M&A transaction — Coherus completes UDENYCA divestiture to Intas for $483.4M upfront; pivots to oncology

Coherus Oncology, Inc.

Closed sale of UDENYCA franchise on April 11, 2025; receives $483.4M cash including $118.4M for inventory.
Eligible for two milestone payments up to $75M total if net sales thresholds met through 2027.
Pro forma cash balance post-close ~$250M; cash runway extended over two years into 2027.
Plans to use proceeds to repurchase $230M of 1.500% Convertible Notes due 2026.
Focus shifts to LOQTORZI, casdozokitug, and CHS-114 novel oncology pipeline.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Coherus Oncology, Inc. completed a disposition involving Intas Pharmaceuticals Ltd. for $483.4 million in cash (closed 2025-04-11).

Action: disposition
Counterparty: Intas Pharmaceuticals Ltd.
Consideration: $483.4 million in cash
Closing: 2025-04-11

Exact text from the filing

On April 11, 2025 (the “Closing Date”), the Company completed the divestiture of the Business (the “UDENYCA Disposition”) to Intas for upfront, all-cash consideration of $483.4 million in cash, inclusive of $118.4 million for UDENYCA product inventory.

View on SEC.gov

28 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-004746

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.